Inflammatory cytokine imbalance after coronary angioplasty: Links with coronary atherosclerosis

Journal of Interventional Cardiology

Volumn 20, Issue 4, 2007, Pages 248-257

  Brunetti, Natale Daniele ^a   Munno, Irene ^b   Pellegrino, Pier Luigi ^a   Ruggiero, Vincenzo ^b   Correale, Michele ^a   Cuculo, Andrea ^a   De Gennaro, Luisa ^a   Campanale, Giulio ^a   Mavilio, Giovanni ^a   Ziccardi, Luigi ^a   Di Biase, Matteo ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; HEART ENZYME; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 2; METAL; RAPAMYCIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG ELUTING STENT; ENZYME RELEASE; FEMALE; HUMAN; INFLAMMATORY INFILTRATE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CASE-CONTROL STUDIES; CORONARY ARTERIOSCLEROSIS; CYTOKINES; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-18; INTERLEUKIN-2; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34547812055     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2007.00266.x     Document Type: Article

References (73)

1. Brunetti ND, Troccoli R, Correale M, et al. C-reactive protein in patients with acute coronary syndrome: Correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings. Int J Cardiol 2006 109 : 248 256.
2. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003 169 : 203 214.
3. Avanzas P, Arroyo-Espliguero R, Cosìn-Sales J, et al. Multiple complex stenoses, high neutrophil count and C-reactive protein levels in patients with chronic stable angina. Atherosclerosis 2004 175 : 151 157.
4. Vainas T, Stassen FRM, de Graaf R, et al. C-reactive protein in peripheral arterial disease: Relation to severity of the disease and to future cardiovascular events. J Vasc Surg 2005 42 : 243 251.
5. Brevetti G, Silvestro A, Di Giacomo S, et al. Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. J Vasc Surg 2003 38 : 374 379.
6. Lakoski SG, Cushman M, Palmas W, et al. The relationship between blood pressure and C-reactive protein in the multi-ethnic study of atherosclerosis (MESA). J Am Coll Cardiol 2005 46 : 1869 1874.
7. Turu MM, Krupinski J, Catena E, et al. Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis 2006 187 : 161 169.
8. Redgrave JN, Lovett JK, Gallagher PJ, et al. Histological assessment of 526 symptomatic carotid plaques in relation to the nature and timing of ischemic symptoms: The Oxford plaque study. Circulation 2006 113 : 2320 2328.
9. Fuster V, Moreno PR, Fayad ZA, et al. Atherothrombosis and high-risk plaque: Part I: Evolving concepts. J Am Coll Cardiol 2005 46 : 937 954.
10. Tanaka A, Shimada K, Sano T, et al. Multiple plaque rupture and C-reactive protein in acute myocardial infarction. J Am Coll Cardiol 2005 45 : 1594 1599.
11. Dokainish H, Pillai M, Murphy SA, et al. Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease: A TACTICS-TIMI-18 substudy. J Am Coll Cardiol 2005 45 : 19 24.
12. Tedgui A, Mallat Z. Cytokines in atherosclerosis: Pathogenic and regulatory pathways. Physiol Rev 2006 86 : 515 581.
13. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res 2004 95 : 858 866.
14. Simon AD, Yazdani S, Wang W, et al. Circulating levels of IL-1beta, a prothrombotic cytokine, are elevated in unstable angina versus stable angina. J Thromb Thrombolysis 2000 9 : 217 222.
15. Biasucci LM, Vitelli A, Liuzzo G, et al. Elevated levels of IL-6 in unstable angina. Circulation 1996 94 : 874 887.
16. Biasucci LM, Liuzzo G, Fantuzzi A, et al. Increasing levels of Interleukin (IL)-1Ra and IL-6 during the first two days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999 99 : 2079 2084.
17. Mizia-Stec K, Mandecki T, Zahorska-Markiewicz B, et al. Selected cytokines and soluble forms of cytokine receptors in coronary artery disease. Eur J Intern Med 2002 13 : 115 122.
18. Mazzone A, De Servi S, Vezzoli M, et al. Plasma levels of Interleukin 2, 6, 10 and phenotypic characterization of circulating T lymphocytes in ischemic heart disease. Atherosclerosis 1999 145 : 369 374.
19. Yamashita H, Shimada K, Seki E, et al. Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris. Am J Cardiol 2003 91 : 133 136.
20. Mallat Z, Henry P, Alouani S, et al. Increased plasma concentrations of Interleukin-18 in acute coronary syndromes. Heart 2002 88 : 467 469.
21. Seta Y, Kanda T, Tanaka T, et al. Interleukin-18 in acute myocardial infarction. Heart 2000 84 : 668.
22. Mallat Z, Corbaz A, Scoazec A, et al. Expression of Interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001 104 : 1598 1603.
23. Whitman SC, Ravisankar P, Daugherty A. Interleukin-18 enhances atherosclerosis in apoliprotein R(-/-) mice through release of interferon-gamma. Circ Res 2002 90 : E34 E38.
24. Waehre T, Halvorsen B, Damas JK, et al. Inflammatory imbalance between IL-10 and TNFα in unstable angina potential plaque stabilizing effects of IL-10. Eur J Clin Invest 2002 32 : 803 810.
25. Okamura H, Tsutsui H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995 378 : 88 91.
26. Anguera I, Miranda-Guardiola F, Bosch X, et al. Elevation of serum levels of the anti-inflammatory cytokine Interleukin-10 and decreased risk of coronary events in patients with unstable angina. Am Heart J 2002 144 : 811 817.
27. Kucharz EJ, Wilk T. Dynamics of serum Interleukin-6 level in patients with acute myocardial infarction. Eur J Intern Med 2000 11 : 253 256.
28. Deten A, Volz HC, Briest W, et al. Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats. Cardiovasc Res 2002 55 : 329 340.
29. Airaghi L, Lettino M, Manfredi MG, et al. Endogenous cytokine antagonists during myocardial ischemia and thrombolytic therapy. Am Heart J 1995 130 : 204 211.
30. Pannitteri G, Marino B, Campa PP, et al. Interleukins 6 and 8 as mediators of acute phase response in acute myocardial infarction. Am J Cardiol 1997 80 : 622 625.
31. Azar RR, McKay RG, Kiernan FJ, et al. Coronary angioplasty induces a systemic inflammatory response. Am J Cardiol 1997 80 : 1476 1478.
32. Gottsauner-Wolf M, Zasmeta G, Hornykewycz S, et al. Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J 2000 21 : 1152 1158.
33. Farb A, Weber DK, Kolodgie KD, et al. Morphological predictors of restenosis after coronary stenting in humans. Circulation 2002 105 : 2974 2980.
34. Gaspardone A, Crea F, Versaci F, et al. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol 1998 82 : 515 518.
35. Almagor M, Keren A, Banai S. Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease. Am Heart J 2003 145 : 248 253.
36. Aggarwal A, Schneider DJ, Terrien EF, et al. Increase in Interleukin-6 in the first hour after coronary stenting: An early marker of the inflammatory response. J Thromb Thrombolys 2003 15 : 25 31.
37. Dominguez-Rodriguez A, Abreu-Gonzalez P, de la Rosa A, et al. Role of endogenous Interleukin-10 production and lipid peroxidation in patients with acute myocardial infarction treated with primary percutaneous transluminal coronary angioplasty Interleukin-10 and primary angioplasty. Int J Cardiol 2005 99 : 77 81.
38. Paroli M, Mariani P, Accapezzato D, et al. Modulation of tachykinin and cytokine release in patients with coronary disease undergoing percutaneous revascularization. Clin Immunol 2004 112 : 78 84.
39. Segev A, Kassam S, Buller CE, et al. Pre-procedural plasma levels of C-reactive protein and Interleukin-6 do not predict late coronary angiographic restenosis after elective stenting. Eur Heart J. 2004 25 : 1029 1035.
40. Kato K, Matsubara T, Iida K, et al. Elevated levels of pro-inflammatory cytokines in coronary artery trombi. Int J Cardiol. 1999 70 : 267 273.
41. Fichtlscherer S, Breuer S, Heeschen C, et al. Interleukin-10 serum levels and systemic endothelial vasoreactivity in patients with coronary artery disease. J Am Coll Cardiol 2004 44 : 44 49.
42. Smith DA, Irving SD, Sheldon J, et al. Serum levels of the anti-inflammatory cytokine Interleukin-10 are decreased in patients with unstable angina. Circulation 2001 104 : 746 749.
43. Fischer CP, Perstrup LB, Berntsen A, et al. Elevated plasma Interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans. Clin Immunol 2005 117 : 152 160.
44. Aggarwal A, Schneider DJ, Sobel BE, et al. Comparison of inflammatory markers in patients with diabetes mellitus versus those without before and after coronary arterial stenting. Am J Cardiol 2003 92 : 924 929.
45. Narins CR, Lin DA, Burton PB, et al. Interleukin-18 and Interleukin-18 binding protein levels before and after percutaneous coronary intervention in patients with and without recent myocardial infarction. Am J Cardiol 2004 94 : 1285 1287.
46. Heusch G, Schulz R, Haude M, et al. Coronary microembolization. J Mol Cell Cardiol 2004 37 : 23 31.
47. Mazzone A, De Servi S, Mazzucchelli I, et al. Increased concentrations of inflammatory mediators in unstable angina: Correlation with serum troponin T. Heart 2001 85 : 571 575.
48. Keso T, Perola M, Laippala P, et al. Polymorphisms within the tumor necrosis factor locus and prevalence of coronary artery disease in middle-aged men. Atherosclerosis 2001 154 : 691 697.
49. DePalma RG, Hayes VW, Treat Cafferata H, et al. Cytokine signatures in atherosclerotic claudicants. J Surg Res 2003 111 : 215 221.
50. Seiler C, Kirkeeide RL, Gould KL. Measurement from arteriograms of regional myocardial bed size distal to any point in the coronary vascular tree for assessing anatomic area at risk. J Am Coll Cardiol 1993 21 : 783 797.
51. Dodge JT, Brown BG, Bolson EL, et al. Intrathoracic spatial location of specified coronary segments on the normal human heart: Applications in quantitative arteriography, assessment of regional risk and contraction, and anatomic display. Circulation 1988 78 : 1167 1180.
52. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count a quantitative method of assessing coronary artery flow. Circulation 1996 93 : 879 888.
53. Heeschen C, Dimmeler S, Hamm CW, et al. Serum level of the antiinflammatory cytokine Interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 2003 107 : 2109 2114.
54. Hillis GS, Terregino CA, Taggart P, et al. Inflammatory cytokines provide limited early prognostic information in emergency department patients with suspected myocardial ischemia. Ann Emerg Med 2003 42 : 337 342.
55. Bennermo M, Held C, Green F, et al. Prognostic value of plasma Interleukin-6 concentrations and the -174 G > C and -572 G > C promoter polymorphisms of the Interleukin-6 gene in patients with acute myocardial infarction treated with thrombolysis. Atherosclerosis 2004 174 : 157 163.
56. Chalikias GK, Tziakas DN, Kaski JC, et al. Interleukin-18: Interleukin-10 ratio and in-hospital adverse events in patients with acute coronary syndrome. Atherosclerosis 2005 182 : 135 143.
57. Chalikias GK, Tziakas DN, Kaski JC, et al. Interleukin-18/Interleukin-10 ratio is an independent predictor of recurrent coronary events during a 1-year follow-up in patients with acute coronary syndrome. Int J Cardiol 2007 117 : 333 339. Epub 2006 July 20.
58. Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999 34 : 1512 1521.
59. Walter DH, Fichtlscherer S, Sellwig M, et al. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001 37 : 839 846.
60. Chew DP, Bhatt DL, Robbins MA, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001 104 : 992 997.
61. Lincoff AM, Kereiakes DJ, Mascelli MA, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001 104 : 163 167.
62. Aggarwal A, Schneider DJ, Terrien EF, et al. Comparison of effects of abciximab versus eptifibatide on C-reactive protein, Interleukin-6, and Interleukin-1 receptor antagonist after coronary arterial stenting. Am J Cardiol 2003 91 : 1346 1349.
63. Merino Otermin A, Artaiz Urdaci M, Bergada Garcia J, et al. Eptifibatide blocks the increase in C-reactive protein concentration after coronary angioplasty. Rev Esp Cardiol 2002 55 : 186 189.
64. Ridker PM, Rifai N, Pfeffer MA, et al. Longterm effects of pravastatin on plasma concentrations of C-reactive protein. Circulation 1999 100 : 230 235.
65. Kim JY, Ko YG, Shim CY, et al. Comparison of effects of drug-eluting stents versus bare metal stents on plasma C-reactive protein levels. Am J Cardiol 2005 96 : 1384 1388.
66. Karha J, Bavry AA, Rajagopal V, et al. Relation of C-reactive protein level and long-term risk of death or myocardial infarction following percutaneous coronary intervention with a sirolimus-eluting stent. Am J Cardiol 2006 98 : 616 618.
67. Gibson CM, Karmpaliotis D, Kosmidou I, et al. Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome. Am J Cardiol 2006 97 : 1473 1477.
68. Gaspardone A, Versaci F, Tomai F, et al. C-Reactive protein, clinical outcome, and restenosis rates after implantation of different drug-eluting stents. Am J Cardiol 2006 97 : 1311 1316.
69. De la Torre-Hernandez JM, Sainz-Laso F, Burgos V, et al. Comparison of C-reactive protein levels after coronary stenting with bare metal versus sirolimus-eluting stents. Am J Cardiol 2005 95 : 748 751.
70. Sardella G, Mariani P, D'Alessandro M, et al. Early elevation of Interleukin-1beta and Interleukin-6 levels after bare or drug eluting stent implantation in patients with stable angina. Thromb Res 2006 117 : 659 664.
71. Gogo PB Jr., Schneider DJ, Watkins MW, et al. Systemic inflammation after drug-eluting stent placement. J Thromb Thrombolys 2005 19 : 87 92.
72. Dibra A, Mehilli J, Braun S, et al. Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. Am Heart J 2005 150 : 344 350.
73. Monraats PS, Pires NM, Schepers A, et al. Tumor necrosis factor-alpha plays an important role in restenosis development. FASEB J 2005 19 : 1998 2004.